Kirsten Marshall
Psychiatric/Mental Health · Fulton, MONPI 1124773650
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 515 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,478, 2.2 times the $1,117 reported in 2022. Among psychiatric/mental health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 515 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$908
- Johnson & Johnson$880
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$861
- Teva Pharmaceuticals USA, Inc.$582
- plus $2K from 11 others
What the payments were for
- Food & beverage$7,85098%
- Education$1592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 85 | $1,266 |
| Alkermes, Inc. | 101 | $1,111 |
| Otsuka America Pharmaceutical, Inc. | 40 | $908 |
| Johnson & Johnson | 50 | $880 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $861 |
| Teva Pharmaceuticals USA, Inc. | 45 | $582 |
| Lundbeck LLC | 21 | $434 |
| AbbVie | 27 | $389 |
| Indivior Inc. | 17 | $336 |
| Axsome Therapeutics, Inc. | 12 | $315 |
| Vanda Pharmaceuticals Inc. | 11 | $259 |
| E.r. Squibb & Sons, L.L.C. | 6 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $157 |
| Supernus Pharmaceuticals, Inc. | 7 | $130 |
| Corium, LLC | 7 | $117 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $52 |
| Sunovion Pharmaceuticals Inc. | 3 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$410
- REXULTI$125
- INVEGA SUSTENNA$118
- ABILIFY MAINTENA$104
- COBENFY$104
How this compares
$8,009 in reported general payments places this provider in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 39 | $311,631 |
| AristadaAripiprazole Lauroxil | 59 | $166,951 |
| Austedo XrDeutetrabenazine | 22 | $165,978 |
| Invega SustennaPaliperidone Palmitate | 50 | $162,496 |
| AustedoDeutetrabenazine | 11 | $161,273 |
| VraylarCariprazine Hcl | 77 | $114,154 |
| Abilify MaintenaAripiprazole | 34 | $85,848 |
| RexultiBrexpiprazole | 47 | $74,412 |
| TrintellixVortioxetine Hydrobromide | 85 | $45,187 |
| LybalviOlanzapine/Samidorphan Malate | 24 | $40,106 |
| CaplytaLumateperone Tosylate | 14 | $23,581 |
| Aripiprazole | 109 | $7,489 |
| Lurasidone Hcl | 52 | $7,243 |
| Vilazodone Hcl | 68 | $7,047 |
| Clozapine | 63 | $6,168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $582 | $327,25033 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,266 | $311,63139 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,111 | $207,05683 claims |
| Johnson & JohnsonInvega Sustenna | $880 | $162,49650 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $908 | $160,26081 claims |
| AbbVieVraylar | $389 | $114,15477 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $157 | $45,18785 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $861 | $23,58114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 565 psychiatric/mental health providers in Missouri.
Other psychiatric/mental health in Fulton
- Aldijana SacicSaint Louis$510K
- Erin DuvallSpringfield$275K
- Laurel OwensLees Summit$246K
- Julie WaterburySaint Louis$135K
- Emily WoukSpringfield$90K
- Kristerpher BrimberryPoplar Bluff$74K
- Matthew LindquistSt Louis$42K
- Stacy EmersonKennett$25K
- Jeffery DavisCreve Coeur$24K
- Kelsey KingsboroughMexico$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.